Ryan Scott

Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

R. Lor Randall, MD, FACS, discusses research in orthopedic oncology that is revolutionizing the management of metastatic bone disease from primary cancers.

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Secondary metastatic involvement in the musculoskeletal system due to primary cancers and MBD affect patient quality of life and create gaps in care.

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

PMV Pharmaceuticals has provided an update on the PYNNACLE trial investigating rezatapopt in TP53 Y220C–mutated solid tumors.

Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.

Treatment with APR-1051 appears safe and well tolerated in patients with advanced solid tumors and select cancer-associated gene alterations.

Nataliya Uboha, MD, PhD, discusses the evolving treatment landscape for patients with gastric, gastroesophageal junction, and esophageal cancers.

Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

Yair Lotan, MD, discusses the treatment paradigm for BCG-unresponsive NMIBC, approved therapeutic options, and factors that influence treatment decisions.

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

The CHMP issued a positive opinion recommending the approval of ribociclib plus endocrine therapy in HR+/HER2– early breast cancer at high risk of recurrence.

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.